AE Wealth Management LLC Sells 4,526 Shares of IDEXX Laboratories, Inc. $IDXX

AE Wealth Management LLC trimmed its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 39.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,071 shares of the company’s stock after selling 4,526 shares during the quarter. AE Wealth Management LLC’s holdings in IDEXX Laboratories were worth $4,518,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in IDXX. Fidelis Capital Partners LLC raised its stake in shares of IDEXX Laboratories by 2.6% during the 3rd quarter. Fidelis Capital Partners LLC now owns 797 shares of the company’s stock worth $509,000 after purchasing an additional 20 shares in the last quarter. New York State Common Retirement Fund raised its position in IDEXX Laboratories by 6.8% during the third quarter. New York State Common Retirement Fund now owns 60,225 shares of the company’s stock worth $38,477,000 after acquiring an additional 3,820 shares in the last quarter. TD Waterhouse Canada Inc. lifted its stake in IDEXX Laboratories by 37.9% in the third quarter. TD Waterhouse Canada Inc. now owns 593 shares of the company’s stock valued at $366,000 after acquiring an additional 163 shares during the last quarter. AustralianSuper Pty Ltd grew its position in shares of IDEXX Laboratories by 419.7% in the 3rd quarter. AustralianSuper Pty Ltd now owns 95,890 shares of the company’s stock valued at $61,263,000 after acquiring an additional 77,438 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of IDEXX Laboratories by 15.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 37,209 shares of the company’s stock worth $23,772,000 after purchasing an additional 4,905 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Activity at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 9,425 shares of the company’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the transaction, the executive vice president directly owned 21,149 shares in the company, valued at approximately $14,874,937.66. This represents a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on IDXX shares. Wall Street Zen downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 17th. Morgan Stanley upped their price objective on IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. BTIG Research raised their price objective on IDEXX Laboratories from $785.00 to $830.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Weiss Ratings downgraded IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday. Finally, UBS Group increased their price target on IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $763.50.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $670.46 on Friday. The firm has a market cap of $53.54 billion, a P/E ratio of 53.17, a price-to-earnings-growth ratio of 3.61 and a beta of 1.67. The business’s 50 day moving average is $705.35 and its 200-day moving average is $660.81. The company has a current ratio of 1.18, a quick ratio of 0.87 and a debt-to-equity ratio of 0.24. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.08. The business had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The firm’s quarterly revenue was up 13.3% on a year-over-year basis. During the same period in the previous year, the company posted $2.80 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Equities research analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.